Adaptimmune Therapeutics upgraded by Guggenheim with a new price target
$ADAP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim upgraded Adaptimmune Therapeutics from Neutral to Buy and set a new price target of $5.00